Trial Profile

A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Who Have Failed Standard Available Therapy

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HPN 536 (Primary)
Indications Carcinoma; Malignant-mesothelioma; Mesothelioma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Harpoon Therapeutics

05 Jun 2024 Number of treatment arms are increased from 2 to 3 by he addition of Experimental: 2 Prime Step IV 900-14000 ng/kg Target arm.
03 May 2023 Status changed from active, no longer recruiting to completed.
09 Sep 2022 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com